CAQ Principal Protected Notes Based Upon A Grp. of Asian Currencies

Corautus Genetics to Present at the Roth Capital Partners New York Conference Presentation to be Webcast Live September 15, 2004 at 8:30 A.M. EDT ATLANTA, Sept. 9 /PRNewswire-FirstCall/ -- Richard E. Otto, President and CEO of Corautus Genetics Inc. (AMEX:CAQ), is scheduled to make a presentation at the Roth Capital Partners New York Conference on Wednesday, September 15, 2004 at 8:30 a.m. (EDT). The conference will be held at the St. Regis Hotel in New York, NY on September 13-15, 2004. Mr. Otto will discuss Corautus' recently initiated GENASIS Phase IIb clinical trial for severe cardiovascular disease, present the Company's broadly enabling technology platform, and review additional development activities and the Company's overall business strategy. A live webcast of the presentation can be accessed by logging onto http://www.wsw.com/webcast/roth4/caq , and a replay will be available for 60 days following the conference. About the Roth Capital Partners New York Conference This annual event is the largest in the nation for emerging growth companies. It provides a concentrated forum where institutional investors can meet the executives of growth companies hand picked by Roth Capital's research team. The conference will highlight approximately 225 companies from industry groups including Health Care/Life Sciences; Consumer Products; Defense & Industrial Technologies; Digital Media, IT & Entertainment; Broadband & Fiber Optics; Gaming; and Business and Banking/Financial Services. For more information about the conference visit: http://www.rothcp.com/Conf%20NY%20Web%20Site/Roth.htm?content=home About Corautus Genetics Corautus Genetics Inc. is a clinical stage biopharmaceutical company dedicated to the development of gene transfer therapy products for the treatment of severe cardiovascular and peripheral vascular disease. Corautus is currently developing a gene transfer product using the Vascular Endothelial Growth Factor-2 (VEGF-2) gene to promote therapeutic angiogenesis in ischemic muscle. In July 2003, Corautus entered into a series of agreements with Boston Scientific Corporation to fund, develop, commercialize and distribute the VEGF-2 gene therapy products. Forward-Looking Statement This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations or our financial condition, benefits from the alliance with Boston Scientific, research, development and commercialization of our product candidates, and in particular whether early-stage clinical trial results are any indication of results in subsequent clinical trials, anticipated trends in our business, manufacture of sufficient and acceptable quantities of our proposed products, approval of our product candidates, meeting additional capital requirements, and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' Annual Report on Form 10-K for the year ended December 31, 2003 (File No. 001-15833) filed March 30, 2004, which are incorporated by reference into this press release. Investor Relations, Jack W. Callicutt of Corautus Genetics Inc., +1-404-526-6200, or fax, +1-404-526-6218; and Media Relations, Justin Jackson of Burns McClellan, on behalf of Corautus Genetics, +1-212-213-0006 DATASOURCE: Corautus Genetics Inc. CONTACT: Investor Relations, Jack W. Callicutt of Corautus Genetics Inc., +1-404-526-6200, or fax, +1-404-526-6218; or Media Relations, Justin Jackson of Burns McClellan, +1-212-213-0006, for Corautus Genetics Inc. Web site: http://www.corautus.com/ http://www.wsw.com/webcast/roth4/caq

Copyright